Published: 7 June 2020
Author(s): Daniela Poli, Emilia Antonucci, Elisa Vignini, Lucia Martinese, Sophie Testa, Paolo Simioni, Vittorio Pengo, Pasquale Pignatelli, Anna Falanga, Lucilla Masciocco, Doris Barcellona, Antonio Ciampa, Paolo Chiarugi, Carmelo Paparo, Walter Ageno, Gualtiero Palareti, START2 Registry investigators
Section: Original article
Intracranial hemorrhage (ICH) is associated with high mortality and severe functional outcome [1]. ICH is frequently associated to antithrombotic treatment and carries a substantial risk of recurrence. This risk impacts on the decision to resume anticoagulation in patients with atrial fibrillation (AF) or venous thromboembolism (VTE).
